Lau CH, Seow KM, Chen KH. The Molecular Mechanisms of Actions, Effects, and Clinical Implications of PARP Inhibitors in Epithelial Ovarian Cancers: A Systematic Review. IJMS 2022;23(15):8125.
DOI: 10.3390/ijms23158125
Konstantinopoulos PA, Ceccaldi R, Shapiro GI, et al. Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer. Cancer Discovery 2015;5(11):1137-54.
DOI: 10.1158/2159-8290.CD-15-0714
Kaye SB. Progress in the treatment of ovarian cancer-lessons from homologous recombination deficiency-the first 10 years. Ann Oncol. 2016;27:i1-3.
DOI: 10.1093/annonc/mdw082
Wright WD, Shah SS, Heyer WD. Homologous recombination and the repair of DNA double-strand breaks. J Biol Chemistry 2018;293(27):10524-35.
DOI: 10.1074/jbc.TM118.000372
Doig KD, Fellowes AP, Fox SB. Homologous Recombination Repair Deficiency: An Overview for Pathologists. Modern Pathology 2023;36(3):100049.
DOI: 10.1016/j.modpat.2022.100049
Herzog TJ, Vergote I, Gomella LG, et al. Testing for homologous recombination repair or homologous recombination deficiency for poly (ADP-ribose) polymerase inhibitors: A current perspective. Eur J Cancer 2023;179:136-46.
DOI: 10.1016/j.ejca.2022.10.021
Kondrashova O, Nguyen M, Shield-Artin K, et al. Secondary somatic mutations restoring RAD51C and RAD51D associated with acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma. Cancer Discov 2017;7:984-98.
DOI: 10.1158/2159-8290.CD-17-0419
Nikkila J, Parplys AC, Pylkäs K, et al. Heterozygous mutations in PALB2 cause DNA replication and damage response defects. Nat. Commun 2013;4:2578.
Kotsopoulos J, Sopik V, Rosen B, et al. Frequency of germline PALB2 mutations among women with epithelial ovarian cancer. Fam Cancer 2017;16:29-34.
DOI: 10.1007/s10689-016-9919-z
Miller RE, Leary A, Scott CL, et al. ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer. Ann Oncol 2020;31(12):1606-22.
DOI: 10.1016/j.annonc.2020.08.2102
González-Martín A, Harter P, Leary A, et al. Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2023;34(10):833-48.
DOI: 10.1016/j.annonc.2023.07.011
Dias MP, Moser SC, Ganesan S, et al. Understanding and overcoming resistance to PARP inhibitors in cancer therapy. Nat Rev Clin Oncol 2021;18(12):773-91.
DOI: 10.1038/s41571-021-00532-x
Kim YN, Shim Y, Seo J, et al. Investigation of PARP Inhibitor Resistance Based on Serially Collected Circulating Tumor DNA in Patients with BRCA -Mutated Ovarian Cancer. Clinical Cancer Research 2023;29(14):2725-34.
DOI: 10.1158/1078-0432.CCR-22-3715
Mirza MR, Monk BJ, Herrstedt J, et al. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. N Engl J Med 2016;375(22):2154-64.
DOI: 10.1056/NEJMoa1611310
LaFargue CJ, Dal Molin GZ, Sood AK, et al. Exploring and comparing adverse events between PARP inhibitors. The Lancet Oncol 2019; 20(1):e15-28.
DOI: 10.1016/S1470-2045(18)30786-1
Poveda A, Floquet A, Ledermann JA, et al. Olaparib Tablets as Maintenance Therapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a BRCA1/2 Mutation (SOLO2/ENGOT-Ov21): A Final Analysis of a Double-Blind, Randomised, Placebo-Controlled, Phase 3 Trial. Obstet Gynecological Survey 2021;76(9):535-6.
DOI: 10.1097/OGX.0000000000000962
Coleman RL, Oza AM, Lorusso D, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017;390(10106):1949-61.
DOI: 10.1016/S0140-6736(17)32440-6
Berek JS, Matulonis UA, Peen U, et al. Safety and dose modification for patients receiving niraparib. Ann Oncol. 2018;29(8):1784-92.
DOI: 10.1093/annonc/mdy181
Zhao D, Long X, Wang J. Dose adjustment of Poly (ADP-Ribose) Polymerase inhibitors in patients with hepatic or renal impairment. Drug Des Devel Ther 2022;14:16:3947-55.
DOI: 10.2147/DDDT.S387920
Korach J, Turner S, Milenkova T, et al. Incidence of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in patients (pts) with a germline (g) BRCA mutation (m) and platinum-sensitive relapsed ovarian cancer (PSR OC) receiving maintenance olaparib in SOLO2: Impact of prior lines of platinum therapy. JCO 2018;36(Suppl.15):5548-5548.
DOI: 10.1200/JCO.2018.36.15_suppl.5548
Kaufman B, Shapira-Frommer R, Schmutzler RK, et al. Olaparib Monotherapy in Patients with Advanced Cancer and a Germline BRCA1/2 Mutation. J Clin Oncol 2015;16;33(3):244-50.
DOI: 10.1200/JCO.2014.56.2728
Ledermann J, Harter P, Gourley C, et al. Olaparib Maintenance Therapy in Platinum Sensitive Relapsed Ovarian Cancer. N Engl J Med 2012;366:1382-92.
DOI: 10.1056/NEJMoa1105535
Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol 2014;15(8):852-61.
DOI: 10.1016/S1470-2045(14)70228-1
Ledermann JA, Harter P, Gourley C, et al. Overall survival in patients with platinum sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Oncol 2016;17(11):1579-89.
DOI: 10.1016/S1470-2045(16)30376-X
Pujade- Lauraine E, Ledermann JA, Selle F, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 2017;18(9):1274-84.
DOI: 10.1016/S1470-2045(17)30469-2
Penson RT, Valencia RV, Cibula D, et al. Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial. J Clin Oncol 2020;38(11):1164-74.
DOI: 10.1200/JCO.19.02745
Pujade-Lauraine, Selle F, Scambia G, et al. Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OEeO/ENGOT-ov38): a phase IIIb trial. Ann Oncol 2023;34(12):1152-64.
DOI: 10.1016/j.annonc.2023.09.3110
Pérez-Fidalgo JA, Cortés A, Guerra E, et al. Olaparib in combination with pegylated liposomal doxorubicin for platinum-resistant ovarian cancer regardless of BRCA status: a GEICO phase II trial (ROLANDO study). ESMO Open 2021;6(4):100212.
DOI: 10.1016/j.esmoop.2021.100212
Pignata S, Oza A, Hall G, et al. Maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer: Outcomes by somatic and germline BRCA and other homologous recombination repair gene mutation status in the ORZORA trial. Gynecol Oncol 2023;172:121-9.
DOI: 10.1016/j.ygyno.2023.03.019
Mirza MR, Monk BJ, Herrstedt J, et al. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. N Engl J Med 2016;375:2154-64.
DOI: 10.1056/NEJMoa1611310
Moore KN, Secord AA, Geller MA, et al. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol 2019;20(5):636-48
DOI: 10.1016/S1470-2045(19)30029-4
Mansor RM, Lundqvist EA, Birrer MJ, et al. Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial. Lancet Oncol 2019;20(10):1409-19.
DOI: 10.1016/S1470-2045(19)30515-7
Kristeleit R, Shapiro GI, Burris HA, et al. A pase I-II study of the oral PARP inhibitor rucaparib in patients with germ-line BRCA 1/2 – mutated ovarian carcinoma or other solid tumors. Clin Cancer Res 2017;23:4095-106.
DOI: 10.1158/1078-0432.CCR-16-2796
Swisher EM, Lin KK, Oza AM, et al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol 2017(1):75-87.
DOI: 10.1016/S1470-2045(16)30559-9
Konecny GE, Oza AM, Tinker AV, et al. Rucaparib in patients with relapsed, primary platinum-sensitive high-grade ovarian carcinoma with germ-line or somatic BRCA mutations: integrated summary of efficacy and safety from the phase 2 study ARIEL 2 (NCT01891344). Gynecol Oncol 2017;145(Suppl.I):2.
DOI: 10.1016/j.ygyno.2017.03.028
Swisher EM, Kwan TT, Oza AM, et al. Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL 2 (Parts 1 and 2). Nat Commun 2021;12:2487.
DOI: 10.1038/s41467-021-22582-6
Coleman R, Oza AM, Lorusso D, et al. Ruaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL 3): a randomized, double blind, placebo-controlled, phase 3 trial. Lancet 2017;390(10106):1949-61.
DOI: 10.1016/S0140-6736(17)32440-6
Kristeleit R, Lisyanskaya A, Fedenco A, et al Rucaparib versus standard-of-care chemotherapy in patients with relpased ovarian cancer and a deleterious BRCA-1 or BRCA-2 mutation (ARIEL4): an international, open-label, randomized, phase 3 trial. Lancet Oncol 2022;23:465-78.
DOI: 10.1016/S1470-2045(22)00122-X
Boussios S, Karithala P, Mochetta M, et al. Veliparib in ovarian cancer: a new synthetically lethal therapeutic approach. Investigational New Drugs 2020;38:181-93.
DOI: 10.1007/s10637-019-00867-4
Donawho CK, Luo Y, Luo Y, et al. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res 2007;13:2728-37.
DOI: 10.1158/1078-0432.CCR-06-3039
Coleman RL, Sill MW, Bell-McGuinn K, et al. A phase II evaluating of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer in patients who carry a germline BRCA 1 or BRCA 2 mutation – an NRG oncology/gynecology oncology group study. Gynecol Oncol 2015;137:386-91.
DOI: 10.1016/j.ygyno.2015.03.042
Kummar S, Oza AM, Fleming GF, et al. Randomized trial of oral cyclophosphamide and veliparib in high-grade serous ovarian, primary peritoneal, or fallopian tube cancers, or BRCA-mutatant ovarian cancer. Clin Cancer Res 2015;21(7):1574-82.
DOI: 10.1158/1078-0432.CCR-14-2565
Coleman RL, Fleming GF, Brady MF, et al. Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer. New Engl J Med 2019;381(25):2403-15.
DOI: 10.1056/NEJMoa1909707
Secord AA, O’Malley DM, Westin SN. Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review. Gynecol Oncol 2021;162(2):482-95.
DOI: 10.1016/j.ygyno.2021.05.018
Liu JF, Barry WT, Birrer M, et al. Overall survival and updated progression-free survivial outcomes in a randomized phase II study of combination cediranib and Olaparib versus Olaparib in relapsed platinum-sensitive ovarian cancer. Ann Oncol 2019;30(4):551-7.
DOI: 10.1093/annonc/mdz018
Nicum S, McGregor N, Austin R, et al. Results of a randomised phase II trial of olaparib, chemotherapy, or olaparib and cediranib in patients with platinum-resistant ovarian cancer. Br J Cancer 2024;130(6):941-50.
DOI: 10.1038/s41416-023-02567-6
Lee J-M, Moore RG, Ghamande S, et al. Cediranib in Combination with Olaparib in Patients without a Germline BRCA1/2 Mutation and with Recurrent Platinum-Resistant Ovarian Cancer: Phase IIb CONCERTO Trial. Clin Cancer Res 2022;28(19):4186-93.
DOI: 10.1158/1078-0432.CCR-21-1733
Colombo N, Tomao F, Benedetti Panici P, et al. Randomized phase II trial of weekly paclitaxel vs. cediranib-olaparib (continuous or intermittent schedule) in platinum-resistant high-grade epithelial ovarian cancer. Gynecol Oncol 2022 164(3):505-13.
DOI: 10.1016/j.ygyno.2022.01.015
Liu JF, Brady MF, Matulonis UA, et al. Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial. J Clin Oncol 2022;40:2138-47.
DOI: 10.1200/JCO.21.02011
Elyashiv O, Lederman J, Parmar G, et al. ICON 9-an international randomized pase III study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapse platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy. Int J Gynecol Cancer 2021;31(1):134-8.
DOI: 10.1136/ijgc-2020-002073
Lee JM, Brady MF, Miller A, et al. Cediranib and olaparib combination comapred with cediranib or olaparib alone, or chemotherapy in platinum-resistant or primary platinum – refractory ovarian cancer: NRG-GY005. J Clin Oncol 2024;42(36):4305-16.
DOI: 10.1200/JCO.24.00683
Maiorano BA, Lorusso D, Maiorano MFP, et al. The interplay between PARP inhibitors and immunotherapy in ovarian cancer: The rationale behind a new combination therapy. Int J Mol Sci 2022;23:3871.
DOI: 10.3390/ijms23073871
Konstantinopoulos PA, Waggoner S, Vidal GA. Single-arm phases 1 and 2 trial of niraparib and pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma. JAMA Oncol 2019;5(8):1141-9.
DOI: 10.1001/jamaoncol.2019.1048
Freyer G, Floquet A, Tredan O, et al. Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group. Nat Commun 2024;15(1):1985.
DOI: 10.1038/s41467-024-45974-w
García-Martínez E, Redondo A, Piulats JM, et al. Are antiangiogenics a Good “partner” for immunotherapy in ovarian cancer? Angiogenesis 2020;23(4):543-57.
DOI: 10.1007/s10456-020-09734-w
Drew Y, Kim JW, Penson RT, et al. Olaparib plus durvalumab, with or without bevacizumab, as treatment in PARP inhibitor -näive platinum sensitive relapsed ovarian cancer: A phase II multi-cohort study. Clin Cancer Res 2024;30(1):50-62.
DOI: 10.1158/1078-0432.CCR-23-2249
González-Martín A, Rubio MJ, Heitz F, et al. Atezolizumab combined with platinum and maintenance niraparib for recurrent ovarian cancer with a platinum-free interval > 6 months: ENGOT -OV41/GEICO 69-O/ANITA phase III trial. J Clin Oncol 2024;42:4294-4304.
DOI: 10.1200/JCO.24.00668
Fumet JD, Limagne E, Thibaudin M, et al. Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment. BMC Cancer 2020; 20(1):748.
DOI: 10.1186/s12885-020-07253-x
Westin SN, Kurnit KC, Fellman B, et al. SOLAR: Phase Ib dose expansion of selumetinib (MEK Inhibitor) and OLAparib (PARP Inhibitor) combination in solid tumors with RAS pathway alterations and in PARP inhibitor-resistant ovarian cancer (abstract). Gynecol Oncol 2023;176(Suppl.1):S33.
DOI: 10.1016/j.ygyno.2023.06.511
Mutch D, Voulgari A, Chen X, et al. Primary results and characterization of patients with exceptional outcomes in a phase 1b study combining PARP and MEK inhibition, with or without anti-PD-L1, for BRCA wild-type, platinum sensitive, recurrent ovarian cancer. Cancer 2024;130(11):1940-51.
DOI: 10.1002/cncr.35222
Wethington SL, Shah PD, Martin L, et al. Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) Trial in Acquired PARP Inhibitor–Resistant Homologous Recombination–Deficient Ovarian Cancer. Clin Cancer Res 2023;29(15):2800-7.
DOI: 10.1158/1078-0432.CCR-22-2444
Illuzzi G, Staniszewska AD, Gill SJ, et al. Preclinical characterization of AZD5305, a next-generation, highly selective PARP1 inhibitor and trapper. Clin Cancer Res 2022;28(21):4724-36.
DOI: 10.1158/1078-0432.CCR-22-0301
Yap TA, Schram AM, Balmaña J, et al. PETRA: first-in-human phase 1/2a trial of the first-in-class next-generation poly(ADP-ribose) polymerase-1 selective inhibitor (PARP1i) saruparib (AZD5305) in patients (pts) with advanced solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations. Presented at: 2024 AACR Annual Meeting; April 5-10, 2024; San Diego, CA. Abstract CT014.
Allarity Therapeutics’ stenoparib shows clear clinical benefit and achieves significant milestone with early conclusion of phase 2 trial in advanced ovarian cancer. News release. Allarity Therapeutics, Inc. May 2, 2024. Accessed May 3, 2024.
Kaufman B, Shapira-Frommer R, Schmutzler RK, et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol 2015;33(3):244-50.
DOI: 10.1200/JCO.2014.56.2728
Moore K, Colombo N, Scambia G, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 2018;379:2495-505.
DOI: 10.1056/NEJMoa1810858
Colombo N, Bradley W, Moore K, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: subgroup analysis by risk in the phase III SOLO1 study. Int J Gynecol Cancer 2020;30(Suppl.4):A76.
DOI: 10.26226/morressier.5fa3ee5d55b1fd4cc4dd93f5
Banerjee S, Moore KN, Colombo N, et al. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2021;22(12):1721-31.
DOI: 10.1016/S1470-2045(21)00531-3
DiSilvestro P, Banerjee S, Colombo N, et al. Overall survival with maintenance olaparib at 7 years of follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: the SOLO1/GOG 3004 trial. J Clin Oncol 2023;41(3):609-17.
DOI: 10.1200/JCO.22.01549
Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011;365:2473-83.
DOI: 10.1056/NEJMoa1104390
Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011;365:2484-96.
DOI: 10.1056/NEJMoa1103799
AstraZeneca: LYNPARZA (Olaparib) Tablets, for Oral Use: Prescribing Information.
Mirza MR, Avall-Lundqvist E, Birrer MJ, et al. Combination of niraparib and bevacizumab versus niraparib alone as treatment of recurrent platinum-sensitive ovarian cancer: a randomized controlled chemotherapy-free study-NSGOAVANOVA2/ENGOT-OV24. J Clin Oncol 2019;37(Suppl:5505).abstract.
DOI: 10.1200/JCO.2019.37.15_suppl.5505
Liu JF, Barry WT, Birrer M, et al. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. Lancet Oncol 2014;15:1207-14.
DOI: 10.1016/S1470-2045(14)70391-2
Liu JF, Barry WT, Birrer M, et al. Overall survival and updated progression-free survival outcomes in a randomized pase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer. Ann Oncol 2019;30:551-7.
DOI: 10.1093/annonc/mdz018
Ray-Coquard I, Pautier P, Pignata S, et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med 2019;381(25):2416-28.
DOI: 10.1056/NEJMoa1911361
Ray-Coquard I, Leary A, Pignata S, et al. Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall results from the PAOLA-1/ENGOT-ov25 trial. Ann Oncol 2023;34(8):681-92.
DOI: 10.1016/j.annonc.2023.05.005
Ministerio de Sanidad. Profesionales de la Salud. Buscador situación financiación medicamentos. Disponible en: https://www.sanidad.gob.es/profesionales/medicamentos.do?metodo=verDetalle&cn=721827
Harter P, Trillsch F, Okamoto A, et al. Durvalumab with Paclitaxel /carboplatin (PC) and bevaciozumab (bev), followed by maintenance durvalumab, bev, and Olaparib in patients (pts) wioth newly diagnosed advanced ovarian cancer (AOC) without a tumor BRCA1/2 mutation (non-tBRCAm): Results from the rancomized, placebo (pbo)-controlled phase III DUO-O trial. J Clin Oncol 2023;41:17;LBA5506.
DOI: 10.1200/JCO.2023.41.17_suppl.LBA5506
Trillsch F, Okamoto A, Kim J, et al. Durvalumab (D)+carboplatin/paclitaxel (CP)+bevacizumab (B) followed by D, B+Olaparib (O) maintenance (mtx) for newly diagnosed advanced ovarian cancer (AOC) without a tumour BRCA1/BRCA 2 mutation (non-tBRCAm): Updated results from DUO-O. Ann Oncol 2024;9(Suppl.5).
DOI: 10.1016/j.esmoop.2024.103550
Monk BJ, Parkinson C, Lim MC, et al. A randomized, phase III trial to evaluate rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45). J Clin Oncol 2022;40(34):3952-64.
DOI: 10.1200/JCO.22.01003
González-Martín A, Pothuri B, Vergote I, et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 2019;381(25):2391-402.
DOI: 10.1056/NEJMoa1910962
González-Martín A, Pothuri B, Vergote I, et al. Progression-free survival and safety at 3,5 years of follow-up: results from the randomized phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer. Eur J Cancer 2023;189:112908.
DOI: 10.1016/j.ejca.2023.04.024
Monk BJ, Barretina-Ginesta MP, Pothuri B, et al. Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT -OV26/GOG-3012 trial. Ann Oncol 2024;35(11):981-92.
DOI: 10.1016/j.annonc.2024.08.2241
Ministerio de Sanidad. Profesionales de la Salud. Buscador situación financiación medicamentos. Disponible en: https://www.sanidad.gob.es/profesionales/medicamentos.do?metodo=verDetalle&cn=720556
Li N, Zhu J, Yin R, et al. Efficacy and safety of niraparib as maintenance treatment in patients with newly diagnosed advanced ovarian cancer using an individualized starting dose (PRIME study): a randomized, double-blind, placebo-controlled, phase 3 trial. Gynecol Oncol 2022;166(Suppl.1):5.
DOI: 10.1016/S0090-8258(22)01298-7
Graybill W, Mirza M, González-Martín A, et al. Efficacy on individualized starting dose (ISD) and fixed starting dose (FSD) of niraparib per investigator-assessment (IA) in newly diagnosed advanced ovarian cancer (OC). Int J Gynecol Cancer 2020;30(Suppl.3):10.
DOI: 10.1136/ijgc-2020-IGCS.13
Hardesty MM, Krivak TC, Wright GS, et al. OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab. Gynecol Oncol 2022;166(2):219-29.
DOI: 10.1016/j.ygyno.2022.05.020
Ministerio de Sanidad. Profesionales de la Salud. Buscador situación financiación medicamentos. Disponible en: https://www.sanidad.gob.es/profesionales/medicamentos.do?metodo=verDetalle&cn=725340
Número de descargas:
272
Número de visitas:
41
Citas:
0
